MiNK Therapeutics, Inc. (INKT)
9.57
-0.65
(-6.40%)
USD |
NASDAQ |
Nov 12, 16:00
9.57
0.00 (0.00%)
After-Hours: 18:59
MiNK Therapeutics Enterprise Value : 43.30M for Nov. 11, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 11, 2026 | 43.30M |
| November 10, 2026 | 42.21M |
| November 09, 2026 | 43.66M |
| November 06, 2026 | 43.94M |
| November 05, 2026 | 42.41M |
| November 04, 2026 | 45.22M |
| November 03, 2026 | 46.19M |
| November 02, 2026 | 47.46M |
| October 30, 2026 | 44.86M |
| October 29, 2026 | 46.62M |
| October 28, 2026 | 46.24M |
| October 27, 2026 | 45.37M |
| October 26, 2026 | 44.35M |
| October 23, 2026 | 45.78M |
| October 22, 2026 | 42.47M |
| October 21, 2026 | 45.32M |
| October 20, 2026 | 41.45M |
| October 19, 2026 | 39.92M |
| October 16, 2026 | 39.15M |
| October 15, 2026 | 41.85M |
| October 14, 2026 | 43.94M |
| October 13, 2026 | 43.33M |
| October 12, 2026 | 44.86M |
| October 09, 2026 | 45.83M |
| October 08, 2026 | 47.26M |
| Date | Value |
|---|---|
| October 07, 2026 | 49.40M |
| October 06, 2026 | 50.82M |
| October 05, 2026 | 53.37M |
| October 02, 2026 | 54.60M |
| October 01, 2026 | 56.07M |
| September 30, 2026 | 55.16M |
| September 29, 2026 | 53.68M |
| September 28, 2026 | 52.91M |
| September 25, 2026 | 53.27M |
| September 24, 2026 | 53.88M |
| September 23, 2026 | 54.14M |
| September 22, 2026 | 52.91M |
| September 21, 2026 | 53.63M |
| September 18, 2026 | 52.61M |
| September 17, 2026 | 50.88M |
| September 16, 2026 | 50.26M |
| September 15, 2026 | 49.35M |
| September 14, 2026 | 52.20M |
| September 11, 2026 | 52.35M |
| September 10, 2026 | 53.02M |
| September 09, 2026 | 51.84M |
| September 08, 2026 | 49.55M |
| September 04, 2026 | 50.52M |
| September 03, 2026 | 48.43M |
| September 02, 2026 | 48.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.270B |
| Alnylam Pharmaceuticals, Inc. | 20.81B |
| Anika Therapeutics, Inc. | 168.04M |
| Savara, Inc. | 926.34M |
| Vericel Corp. | 2.957B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.128M |
| Total Expenses (Quarterly) | 3.128M |
| EPS Diluted (Quarterly) | -0.6227 |
| Earnings Yield | -25.05% |
| Normalized Earnings Yield | -25.62 |